The Canadian Intellectual Property Office (“CIPO”) has issued a notice of allowance for IntelGenx’s (TSXV:IGX; OTCQX:IGXT) first Canadian patent application for its VersaFilm technology.
Entitled, “Loxapine Film Oral Dosage Form,” the patent, when issued, would cover the use of loxapine in an oral transmucosal film for the treatment of schizophrenia or bipolar 1 disorder through 2037.
This is also the company’s first patent application to receive a notice of allowance in relation to its Loxapine VersaFilm project.
“This notice of allowance from CIPO is a significant development in our Loxapine VersaFilm project as it confirms our leading approach in developing oral films to provide patients with alternative oral treatment solutions,” Dr. Horst Zerbe, president and CEO of IntelGenx, said in a statement.
